Trials / Withdrawn
WithdrawnNCT05809687
Phase 3 Trial to Evaluate the Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A
Evaluate Efficacy and Safety of DKP21102_B Added on to DKP21102_A Compared With DKP21102_A in Mixed Dyslipidemia Patients
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Dongkwang Pharm. Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
Phase 3 study to evaluate the efficacy and safety of DKP21102\_B Added on to DKP21102\_A Compared with DKP21102\_A
Detailed description
Phase 3 study to evaluate the efficacy and safety of DKP21102 in patients with mixed dyslipidemia where LDL-C is properly controlled but triglyceride and HDL-C levels are not regulated by DKP21102\_A alone.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DKP21102_C | Placebo |
| DRUG | DKP21102_B | Treatment |
| DRUG | DKP21102_A | Active Control |
Timeline
- Start date
- 2025-01-01
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
- First posted
- 2023-04-12
- Last updated
- 2024-10-24
Source: ClinicalTrials.gov record NCT05809687. Inclusion in this directory is not an endorsement.